stockportfolio.pro
West Pharmaceutical Services, Inc. (WST)
Healthcare · Medical Instruments & Supplies · NYSE
West Pharmaceutical Services, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.51B | $1.60B | $1.72B | $1.84B | $2.15B | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Gross profit | $501.40M | $512.90M | $545.40M | $605.70M | $767.80M | $1.18B | $1.14B | $1.13B | $998.50M | $1.10B |
| Net income | $143.60M | $150.70M | $206.90M | $241.70M | $346.20M | $661.80M | $585.90M | $593.40M | $492.70M | $493.70M |
| Net margin | 9.5% | 9.4% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
Source: West Pharmaceutical Services, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into WST stock?
At today's market cap of $23.64B, West Pharmaceutical Services, Inc. is priced for free-cash-flow growth of about 20.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $468.90M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 9.5%/yr over the last five fiscal years and revenue 7.4%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of West Pharmaceutical Services, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track WST in your portfolio →
West Pharmaceutical Services, Inc. financial history by metric
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services, Inc. — frequently asked questions
What is West Pharmaceutical Services, Inc.'s revenue?
West Pharmaceutical Services, Inc. (WST) reported revenue of $3.07B for fiscal year 2025, up 6.3% from the prior year, according to its SEC filings.
Is West Pharmaceutical Services, Inc. profitable?
Yes. WST earned net income of $493.70M in fiscal 2025, a net margin of 16.1%.
What is WST's P/E ratio?
West Pharmaceutical Services, Inc. trades at a price-to-earnings ratio of about 44.7 based on the latest data in our nightly-refreshed cache.
How fast is West Pharmaceutical Services, Inc. growing?
WST's revenue grew at roughly 7.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does West Pharmaceutical Services, Inc. have?
As of fiscal year 2025, WST carried roughly $202.80M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is West Pharmaceutical Services, Inc.'s gross margin?
WST's gross margin was 35.9% in fiscal 2025 — gross profit of $1.10B on revenue of $3.07B.
What is West Pharmaceutical Services, Inc.'s market cap?
West Pharmaceutical Services, Inc. (WST) has a market capitalization of about $23.64B, based on the latest data in our nightly-refreshed cache.
When does West Pharmaceutical Services, Inc.'s fiscal year end?
WST's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into WST stock?
At today's market cap of $23.64B, West Pharmaceutical Services, Inc. is priced for free-cash-flow growth of about 20.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $468.90M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 9.5%/yr over the last five fiscal years and revenue 7.4%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from West Pharmaceutical Services, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.